AA
MRNA icon

ALPS Advisors’s Moderna MRNA Stock Holding History

ALPS Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,406
Closed -$432K – 1093
2022
Q4 		$432K Sell
2,406
-10
-0.4% -$1.64K ﹤0.01% 634
2022
Q3 		$286K Buy
2,416
+81
+3% +$12.3K ﹤0.01% 879
2022
Q2 		$334K Sell
2,335
-24
-1% -$3.43K ﹤0.01% 719
2022
Q1 		$406K Buy
2,359
+1,492
+172% +$251K ﹤0.01% 472
2021
Q4 		$220K Buy
867
+18
+2% +$5.26K ﹤0.01% 869
2021
Q3 		$327K Buy
+849
New +$313K ﹤0.01% 838

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ALPS Advisors's MRNA Position: Q1 2023 in Review

ALPS Advisors sold out of Moderna (MRNA) in Q1 2023, closing a stake of 2,406 shares — an estimated $432K sold.

ALPS Advisors first reported a position in MRNA in Q3 2021 and held it in 6 quarters. The position peaked at $432K in Q4 2022. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • ALPS Advisors reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
  • ALPS Advisors sold 2,406 Moderna shares in Q1 2023, an estimated $432K.
  • ALPS Advisors first reported a position in Moderna in Q3 2021 and held it in 6 quarters.
  • ALPS Advisors's Moderna position peaked at $432K in Q4 2022.
  • 1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on ALPS Advisors's 13F filing for Q1 2023, filed 10 May 2023.